EUVIMEDEUVIMED entdecken
Open Access

Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses

Ben S Ou iD, Julie Baillet iD, Maria V Filsinger Interrante iD, Julia Z Adamska iD, Xueting Zhou iD, Olivia M Saouaf iD, Jerry Yan iD, John H Klich iD, Carolyn K Jons iD, Emily L Meany iD, Adian S Valdez iD, Lauren Carter iD und 3 weitere

Science Advances · 2024

DOI: 10.1126/sciadv.adn7187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Ben S Ou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, COVID-19 Vaccines, Nanoparticles, Saponins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past few decades, the development of potent and safe immune-activating adjuvant technologies has become the heart of intensive research in the constant fight against highly mutative and immune evasive viruses such as influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and human immunodeficiency virus (HIV). Herein, we developed a highly modular saponin-based nanoparticle platform incorporating Toll-like receptor agonists (TLRas) including TLR1/2a, TLR4a, and TLR7/8a adjuvants and their mixtures. These various TLRa–saponin nanoparticle adjuvant constructs induce unique acute cytokine and immune-signaling profiles, leading to specific T helper responses that could be of interest depending on the target disease for prevention. In a murine vaccine study, the adjuvants greatly improved the potency, durability, breadth, and neutralization of both COVID-19 and HIV vaccine candidates, suggesting the potential broad application of these adjuvant constructs to a range of different antigens. Overall, this work demonstrates a modular TLRa-SNP adjuvant platform that could improve the design of vaccines and affect modern vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicCOVID-19 VaccinesNanoparticlesSaponinsSARS-CoV-2Toll-Like Receptor AgonistsAnimalsHumansMiceAdjuvants, VaccineAIDS VaccinesCOVID-19Cytokines

Substanzen

Adjuvants, ImmunologicAdjuvants, VaccineAIDS VaccinesCOVID-19 VaccinesCytokinesSaponinsToll-Like Receptor Agonists

Autor:innen und Institutionen

  • Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
  • Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305, USA.
  • Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA.
  • Stanford Biophysics Program, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Stanford Medical Scientist Training Program, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.

ORCID-Profile: Ben S Ou, Julie Baillet, Maria V Filsinger Interrante, Julia Z Adamska, Xueting Zhou, Olivia M Saouaf, Jerry Yan, John H Klich, Carolyn K Jons, Emily L Meany, Adian S Valdez, Lauren Carter, Bali Pulendran, Neil P King, Eric A Appel

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • NCRR NIH HHS

Zitieren

APA

Ou, B. S., Baillet, J., Filsinger Interrante, M. V., Adamska, J. Z., Zhou, X., Saouaf, O. M., Yan, J., Klich, J. H., Jons, C. K., Meany, E. L., Valdez, A. S., Carter, L., Pulendran, B., King, N. P., & Appel, E. A. (2024). Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Science Advances. https://doi.org/10.1126/sciadv.adn7187

Vancouver

Ou BS, Baillet J, Filsinger Interrante MV, Adamska JZ, Zhou X, Saouaf OM, et al. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Science Advances. 2024. doi:10.1126/sciadv.adn7187

BibTeX
@article{Ou2024,
  author = {Ou, Ben S and Baillet, Julie and Filsinger Interrante, Maria V and Adamska, Julia Z and Zhou, Xueting and Saouaf, Olivia M and Yan, Jerry and Klich, John H and Jons, Carolyn K and Meany, Emily L and Valdez, Adian S and Carter, Lauren and Pulendran, Bali and King, Neil P and Appel, Eric A},
  title = {Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adn7187}
}
Kostenlos starten →